Replies to post #6510 on Momenta Pharmaceuticals, Inc. (MNTA)

[DewDiligence]

It’s unclear to me how item #5 pertains to MNTA’s patents; I won’t be surprised if that specific request is denied. Also, I don’t think MNTA will get access to Amphastar’s entire ANDA, but rather to the portion of it pertaining to manufacturing.

[dav1234]

They forgot to ask for kitchen sink

[investorgold2002]

grthzgd - judge's order has restricted this even more

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=68014574

1) release testing related to
detecting 1,6-anhydro ring structures,

2) release testing related
to sequencing of tetrasaccharides,

and 3) master batch records.
Defendants shall produce the requested documents on or before the
close of business Monday, October 17, 2011.

So no ANDA, DMF OR FDA Communications.


This is ok, as 1)2) and 3) addresses HOW IN THEIR(SUPPLIER) COMMERCIAL MANUFACTURING THEY ENSURE THE ABOVE 2 TESTING
(1-6 ANH and sequencing of tetra)

This judge wants to get to the bottom of the case.

Yet, Ampha promptly filed under seal an opposition to this limited discovery.